
|Videos|December 9, 2021
Recent Data Surrounding the Appropriate Candidates for Long-Acting Cabotegravir for HIV Prevention
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Advertisement
Pharmacy Times spoke with Dr. Elizabeth Sherman, PharmD, about her session at the ASHP Midyear 2021 conference, titled "Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection”.
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Round-Up: Every Most Favored Nation Agreement With the Trump Administration
2
Study Finds Persistent Gaps in Diagnoses for Depression and Chronic Conditions After COVID-19
3
Dato-DXd Granted Priority Review as First-Line Therapy for Metastatic Triple-Negative Breast Cancer
4
Expert: Early Phase 1 Data Shows KTX-1001 Targeting NSD2 Offers Promise for Relapsed/Refractory Multiple Myeloma
5


























